Skip to content

Accel-Rx Health Sciences Accelerator to Partner with BDC Venture Capital

MaRS Innovation co-partner in pan-Canadian effort to help create up to 20 leading start-up companies

Accel-Rx logoCEBIO International Conference, San Diego – June 25, 2014: BDC Venture Capital and the Accel-Rx Health Sciences Accelerator (Accel-Rx) announced today a collaboration to provide critical seed funding to new and emerging Canadian health sciences companies.

This announcement was covered in TechVibes, PE HUB and BetaKit.

Accel-Rx AnnouncementTogether, Accel-Rx, BDC Venture Capital, and CDRD Ventures Inc. (CVI) which will provide the initial management to launch Accel-Rx operations, would focus on maximizing new health sciences company creation, and ensuring start-ups have the resources they need to grow and become a new generation of strong health sciences companies.

Accel-Rx brings together five of Canada’s leading health sciences Centres of Excellence for Commercialization and Research (CECR) to foster cross-Canadian cooperation and directly addressing the health science company creation challenge in Canada. They include:

The accelerator will help make a connection between: promising technologies; experts in drug development, clinical/regulatory affairs, deal-making and finance; entrepreneurs and mentors; and R&D infrastructure and resources.

Continue Reading

Portfolio Snapshot: Minuum debuts on Google Glass, Crowdmark named most innovative at SIIA

There’s been lots of activity in MI’s portfolio this week (and it’s only Wednesday). Read down for what you need to know about Whirlscape, Crowdmark, OtoSim, and ApneaDx.

Whirlscape logoWhirlscape launches Google Glass demo video

Whirlscape’s Minuum keyboard nabbed a four-star review from CNET’s editors only days before announcing their technology is now available for Google Glass. Watch the UTEST graduate‘s newest demo video.

Reaction coverage: BNN, the Telegraph (U.K.), WPRO (radio), CNET, Mashable, TechCrunch, Mobile Syrup and Android Central, among various other tech blogs.

Crowdmark Logo: Grade BetterCrowdmark named “Most Innovative” at SIIA conference

The Education Division of the Software & Information Industry Association (SIIA) showcased some of the newest and most innovative products in the education technology market, and recognized the best among them as part of the Innovation Incubator program at the 13th annual Education Industry Summit, the leading conference for the K-12 and postsecondary education technology market, held May 12-14 at the Palace Hotel in San Francisco.

From their blog:

Crowdmark was named Most Innovative among more than 50 applicants,

Continue Reading

MaRS Innovation Statement on 2014 Ontario Budget

TORONTO, ON (May 2, 2014) – MaRS Innovation congratulates the government’s deepened commitment to support the life sciences through research and innovation funding. In particular, the new $30 million Life Sciences Seed Venture Capital Fund will create a partnership between the Province of Ontario, the private sector and hospital foundations to finance Ontario-based life sciences companies.

Dr. Raphael Hofstein
Dr. Raphael Hofstein, president & CEO, MaRS Innovation.

“As co-designers of this venture capital fund and one of its many champions, MaRS Innovation welcomes this news,” says Dr. Raphael (Rafi) Hofstein, president and CEO. “We look forward to the strong collaborations it will foster with our colleagues in the Government of Ontario, private industry and the hospital community.”

“By their nature and the need for regulation, life sciences companies take considerable time to mature products and their underlying technologies. Expanding the funding available during this critical stage through this unique public-private partnership will give more Ontario start-ups emerging with disruptive technologies from the province’s academic institutions the financing they need to succeed and thrive,” says Hofstein.

Continue Reading

MI’s Rafi Hofstein featured in Biotechnology Focus

Dr. Raphael Hofstein (left), the Honourable Minister Reza Moridi (centre) and Dr. Mark
MI’s Dr. Raphael Hofstein (left), the Honourable Minister Reza Moridi (centre) and Dr. Mark Poznansky of the Ontario Genome Institute on the January 2014 cover of Biotechnology Focus.

In a January 24, 2014 Biotechnology Focus cover article, author Shawn Lawrence discusses MaRS Innovation President and CEO Dr. Raphael (Rafi) Hofstein‘s recent visit to learn more of the emerging science and technology markets in Singapore and Japan.

The trip allowed Hofstein to discuss current MI projects, specifically start-ups XLV Diagnostics Inc. and DVLR Therapeutics Inc., whose products could benefit from Singapore’s proximity to medical technology markets in India and China.

Hofstein joined other delegates from Canada, including Dr. Mark Poznansky, president and CEO of the Ontario Genome Institute (OGI).

Continue Reading

Xagenic founder Shana Kelley’s MRI blog post on bringing research to market

U of T professor shares tips to her team’s commercialization success

Xagenic logo CroppedWhen it comes to bringing research from the lab to the market, the University of Toronto’s Dr. Shana Kelley knows firsthand what it takes. She’s co-founder of Xagenic, a MaRS Innovation and U of T start-up company that’s developed the first lab-free molecular diagnostic platform with a 20-minute time-to-result based on her research with fellow U of T colleague Professor Edward Sargent.

Xagenic recently announced a Series B financing announcement following their successful $10 million Series A round and more than $2 million seed funding round.

In her guest blog post for the Ministry of Research and Innovation, Kelley outlines what she’s learned through her experience in the commercialization process (emphasis ours):

1. When ready to commercialize, look in your own backyard for investment and support

Shana Kelley, co-founder of Xagenic Inc.
Dr. Shana Kelley, co-founder of Xagenic Inc. and University of Toronto professor.

When the Xagenic technology was mature enough to consider commercialization, we started to call venture investors all over the world to see if we could get them to back the company.  We always got the meetings we wanted, and lots of enthusiasm and encouragement, but it was difficult to get people engaged. We were fortunate to get seed funding from a group of local organizations including MaRS Innovation, Ontario Institute for Cancer Research, the Innovation Acceleration Fund (IAF), and Ontario Centres of Excellence and then finally found the group that would eventually be our Series A lead investors, CTI Life Sciences Fund.

With CTI, we immediately got the traction we had been looking for from a venture investor that indicated genuine interest in the company. When we later made the rounds for the Series B investment outside of Canada, we repeatedly heard the comment: “we’re glad to see you could do the Series A in your own backyard.”

When I probed about why this was important, I found that the investment community thinks it is important to have your early investors as close geographically as possible. The level of interaction when a company gets off the group needs to be fairly intense — being geographically closer helps entrepreneurs and investors keep in better contact. This is definitely not a hard-and-fast rule, but I found it interesting that many investors had this perception. And it creates a particular challenge for Canadian companies given how little venture capital is available locally!

Continue Reading

MaRS Innovation President and CEO Named to Ontario Health Innovation Council

Council members include MI’s Raphael Hofstein and MI Board Chair Dr. Robert Bell

On November 20, the Government of Ontario launched the Ontario Health Innovation Council to support health innovation in Ontario. Dr. Raphael Hofstein, president and CEO of MaRS Innovation, was named to the council.

Screen Shot 2013-12-18 at 4.33.09 PM
Members of the Ontario Health Innovation Council, including MaRS Innovation’s president and CEO Dr. Raphael Hofstein (third from left), pose after the initial announcement.

By becoming a member of the Council, Hofstein will assist in identifying evidence-based opportunities in Ontario’s healthcare space and advancing them into practice on a global scale.

Continue Reading

Cellax profiled in SciBX; MaRS Innovation’s MSc PoP program cited in National Post supplement

CellaxThe Cellax technology was profiled in a recent issue of  SciBX (subscription necessary). MaRS Innovation is mentioned in the article as the technology’s commercialization agent.

Here’s an excerpt:

Ontario Institute for Cancer Research scientists have developed glycopolymer-conjugated docetaxel nanoparticles that outperform Abraxane in mouse models of breast cancer. The Ontario Institute for Cancer Research (OICR) is backing the program with $1.5 million to take it to the clinic. The expectation is that the product’s ability to target the tumor stroma rather than the tumor itself will differentiate it from Abraxane and other chemotherapeutic formulations.”

Continue Reading

Call for Applications: MaRS Innovation seeks applicants for early-stage MSc POP projects

Government of Ontario logoMaRS Innovation (MI) seeks applicants for the Medical Sciences Proof-of-Principle (MSc PoP) program, which supports early-stage medical science technologies and allows their founding teams to conduct crucial proof-of-principle work.

Through the two-year MSc POP program, MI will distribute funding awards to qualified applicants within its membership on behalf of the Ministry of Research and Innovation (MRI). Funds are available in $25,000 or $75,000 grants.

“At MaRS Innovation, the PoP program functions as a kind of internal Dragons’ Den,” says Dr. Raphael Hofstein, president and CEO of MaRS Innovation. “For three years, we’ve used a panel of industry leaders to hear pitches from the founding teams of the most promising technologies in our intellectual property pipeline. Based on their assessments, the strongest projects receive PoP funding to fuel their prototyping and other proof-of-principle work.”

Continue Reading
Back To Top